Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00602667 · OUTCOME

Neurocognitive Performance Related to Visual-spatial Reasoning as Measured by Visual Perception T-scores

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma · Source last updated 2026-05-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
score on a scale
Interval / dispersion
Standard Deviation
Time frame
Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy

What was measured

Scores measuring visual-spatial reasoning were obtained from Visual Perception T-scores on the Beery Visual Motor Integration (VMI) instrument. Higher scores indicate better performance. The normative mean is 50 with a standard deviation of 10.

Analysis population: Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.

Groups in this outcome

Low-Risk Group

Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.

Intermediate-Risk Group

Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.

High-Risk Group

Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Low-Risk Group22
Intermediate-Risk Group53
High-Risk Group14

Reported measurements

Baseline

Analysis denominator · Participants

GroupSource count
Low-Risk Group1
Intermediate-Risk Group9
High-Risk Group3
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group66.0Not reportedNot reportedNot reportedNot reported
Intermediate-Risk Group31.612.2Not reportedNot reportedNot reported
High-Risk Group33.79.5Not reportedNot reportedNot reported
Prior to Maintenance Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group2
Intermediate-Risk Group14
High-Risk Group2
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group32.07.1Not reportedNot reportedNot reported
Intermediate-Risk Group40.212.2Not reportedNot reportedNot reported
High-Risk Group56.08.5Not reportedNot reportedNot reported
Completion of Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group3
Intermediate-Risk Group16
High-Risk Group2
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group39.016.4Not reportedNot reportedNot reported
Intermediate-Risk Group39.812.3Not reportedNot reportedNot reported
High-Risk Group18.526.2Not reportedNot reportedNot reported
12 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group6
Intermediate-Risk Group21
High-Risk Group1
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group42.314.7Not reportedNot reportedNot reported
Intermediate-Risk Group41.014.5Not reportedNot reportedNot reported
High-Risk Group33.0Not reportedNot reportedNot reportedNot reported
24 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group11
Intermediate-Risk Group31
High-Risk Group3
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group43.415.0Not reportedNot reportedNot reported
Intermediate-Risk Group40.113.4Not reportedNot reportedNot reported
High-Risk Group32.08.9Not reportedNot reportedNot reported
36 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group11
Intermediate-Risk Group26
High-Risk Group5
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group51.217.8Not reportedNot reportedNot reported
Intermediate-Risk Group41.013.6Not reportedNot reportedNot reported
High-Risk Group48.818.7Not reportedNot reportedNot reported
48 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group13
Intermediate-Risk Group24
High-Risk Group3
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group48.624.9Not reportedNot reportedNot reported
Intermediate-Risk Group46.111.3Not reportedNot reportedNot reported
High-Risk Group42.78.3Not reportedNot reportedNot reported
60 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group14
Intermediate-Risk Group19
High-Risk Group2
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group43.118.8Not reportedNot reportedNot reported
Intermediate-Risk Group42.313.3Not reportedNot reportedNot reported
High-Risk Group36.012.7Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        66.0
      2. group Id
        OG001
        spread
        12.2
        value
        31.6
      3. group Id
        OG002
        spread
        9.5
        value
        33.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        9
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    Baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        7.1
        value
        32.0
      2. group Id
        OG001
        spread
        12.2
        value
        40.2
      3. group Id
        OG002
        spread
        8.5
        value
        56.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        14
      3. group Id
        OG002
        value
        2
      units
      Participants
    title
    Prior to Maintenance Therapy
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        16.4
        value
        39.0
      2. group Id
        OG001
        spread
        12.3
        value
        39.8
      3. group Id
        OG002
        spread
        26.2
        value
        18.5
    denoms
    1. counts
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        16
      3. group Id
        OG002
        value
        2
      units
      Participants
    title
    Completion of Therapy
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        14.7
        value
        42.3
      2. group Id
        OG001
        spread
        14.5
        value
        41.0
      3. group Id
        OG002
        value
        33.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        6
      2. group Id
        OG001
        value
        21
      3. group Id
        OG002
        value
        1
      units
      Participants
    title
    12 Months Off Therapy
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        15.0
        value
        43.4
      2. group Id
        OG001
        spread
        13.4
        value
        40.1
      3. group Id
        OG002
        spread
        8.9
        value
        32.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        11
      2. group Id
        OG001
        value
        31
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    24 Months Off Therapy
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        17.8
        value
        51.2
      2. group Id
        OG001
        spread
        13.6
        value
        41.0
      3. group Id
        OG002
        spread
        18.7
        value
        48.8
    denoms
    1. counts
      1. group Id
        OG000
        value
        11
      2. group Id
        OG001
        value
        26
      3. group Id
        OG002
        value
        5
      units
      Participants
    title
    36 Months Off Therapy
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        24.9
        value
        48.6
      2. group Id
        OG001
        spread
        11.3
        value
        46.1
      3. group Id
        OG002
        spread
        8.3
        value
        42.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        13
      2. group Id
        OG001
        value
        24
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    48 Months Off Therapy
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        18.8
        value
        43.1
      2. group Id
        OG001
        spread
        13.3
        value
        42.3
      3. group Id
        OG002
        spread
        12.7
        value
        36.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        14
      2. group Id
        OG001
        value
        19
      3. group Id
        OG002
        value
        2
      units
      Participants
    title
    60 Months Off Therapy
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    2. group Id
      OG001
      value
      53
    3. group Id
      OG002
      value
      14
    units
    Participants
description
Scores measuring visual-spatial reasoning were obtained from Visual Perception T-scores on the Beery Visual Motor Integration (VMI) instrument. Higher scores indicate better performance. The normative mean is 50 with a standard deviation of 10.
dispersion Type
Standard Deviation
groups
  1. description
    Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.
    id
    OG000
    title
    Low-Risk Group
  2. description
    Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
    id
    OG001
    title
    Intermediate-Risk Group
  3. description
    Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.
    id
    OG002
    title
    High-Risk Group
param Type
MEAN
population Description
Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.
reporting Status
POSTED
time Frame
Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy
title
Neurocognitive Performance Related to Visual-spatial Reasoning as Measured by Visual Perception T-scores
type
SECONDARY
unit Of Measure
score on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice